Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year's review.
Dennis MujuniDianah Linda KasemireIvan IbandaJoel KabugoAndrew NsawotebbaJody E PhelanRobert Kaos MajwalaDidas TugumisirizeAbdunoor NyombiBeatrice OrenaIrene TuryahabweHenry ByabajunguDiana NadungaKenneth MusisiMoses Lutakoome JolobaWilly SsengoobaPublished in: BMC infectious diseases (2022)
Our study reveals a high proportion of mutations known to confer high-level fluoroquinolone drug-resistance among patients with rifampicin and/or isoniazid drug resistance. Utilizing routinely generated laboratory data from existing molecular diagnostic methods may aid real-time surveillance of emerging tuberculosis drug-resistance in resource-limited settings.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- multidrug resistant
- end stage renal disease
- pulmonary tuberculosis
- newly diagnosed
- acinetobacter baumannii
- ejection fraction
- chronic kidney disease
- public health
- hiv aids
- prognostic factors
- peritoneal dialysis
- electronic health record
- hiv infected
- patient reported
- antiretroviral therapy
- drug induced